Infiltrative Heart Diseases Mary O. Gray, M.D. Professor of - - PDF document

infiltrative heart diseases
SMART_READER_LITE
LIVE PREVIEW

Infiltrative Heart Diseases Mary O. Gray, M.D. Professor of - - PDF document

12/19/15 Infiltrative Heart Diseases Mary O. Gray, M.D. Professor of Medicine (Cardiology) UC San Francisco mary.gray@ucsf.edu No Disclosures Increased Left Ventricular Mass and Thick Walls Hypertrophic Hypertension & Cardiomyopathy


slide-1
SLIDE 1

12/19/15 1

Infiltrative Heart Diseases

Mary O. Gray, M.D. Professor of Medicine (Cardiology) UC San Francisco mary.gray@ucsf.edu

No Disclosures

Increased Left Ventricular Mass and Thick Walls

Hypertrophic Cardiomyopathy Hypertension & Kidney Disease Cardiac Amyloidosis Mucopoly- Saccharidosis Cardiac Sarcoidosis Friedreich Ataxia

slide-2
SLIDE 2

12/19/15 2

Endomyocardial Biopsy: Alcian Blue Pathophysiology and Treatment of Cardiac Amyloidosis

MA Gertz, A Dispenzieri, and T Sher Nature Reviews Cardiology 12, 91-102 (2015)

slide-3
SLIDE 3

12/19/15 3

Classification of Cardiac Amyloid Types

Amyloidosis Type Precursor Comment

Light Chain AL Immunoglobulin Light Chain Plasma Cell Dyscrasia Mutant Transthyretin TTR Point Mutation Autosomal Dominant Wild-Type Transthyretin None Senile Amyloidosis Amyloid A Serum Amyloid A Sustained Inflammation Isolated Atrial Amyloid Atrial Natriuretic Factor Atrial Fibrillation

slide-4
SLIDE 4

12/19/15 4

Serum Free Light Chain Assay Bone Marrow Biopsy: λ Light Chains

slide-5
SLIDE 5

12/19/15 5

Subcutaneous Fat Aspirate: Congo Red

Positive Non-Ischemic Cardiomyopathy

Serum and Urine Immunofixation. Serum Free Light Chain Assay. Bone Marrow Biopsy and Fat Aspiration with Congo Red Staining

AL Likely. Confirm with Mass Spectroscopy.

slide-6
SLIDE 6

12/19/15 6

Diagnosis, Prognosis, and Therapy

  • f Transthyretin Amyloidosis

MA Gertz, MD Benson, PJ Dyck, et al. JACC 2015;66:2451-2466

slide-7
SLIDE 7

12/19/15 7

Transthyretin (TTR)

Transporter of Thyroxine and Retinol

Positive Non-Ischemic Cardiomyopathy

Serum and Urine Immunofixation. Serum Free Light Chain Assay.

Mass Spectroscopy and TTR Gene Sequencing

TTR Wild-Type or Mutant Fat Aspirate Endomyocardial Biopsy

Negative

slide-8
SLIDE 8

12/19/15 8

Evaluation to Diagnose TTR Amyloidosis

Results Suggestive of ATTR

Physical Examination Autonomic Neuropathy

Serum Immunofixation and Immunoglobulin Free LC Assay LC Amyloidosis Excluded

Urine Tests Nephrotic Range Proteinuria

Tissue and Strain Doppler Echocardiography Diastolic Dysfunction

Cardiac Magnetic Resonance Chamber Infiltration

Results Suggestive of ATTR

Radionuclide Imaging Cardiac Amyloid Detection

Cardiac Biomarkers Elevated Troponin Brain Natriuretic Peptide

Medical History Carpal Tunnel Syndrome

Tissue Biopsy: less invasive Fat and Bone Marrow

Tissue Biopsy: more invasive Heart, Nerve, Kidney

Mass Spectroscopy TTR Amyloid Deposits

slide-9
SLIDE 9

12/19/15 9

CMR without Gadolinium: Wall Thickening Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis

M Fontana, S Pica, P Reant, et al. Circulation 2015;132:1570-1579

slide-10
SLIDE 10

12/19/15 10

CMR with Late Gadolinium Enhancement LGE Pattern and Cardiac Amyloid Burden

slide-11
SLIDE 11

12/19/15 11

LGE Pattern and Cumulative Survival Hypothesis: Cardiac Amyloid Progression

slide-12
SLIDE 12

12/19/15 12

Heart Failure with Preserved Ejection Fraction

HFpEF Therapy and Cardiac Amyloidosis

Loop Diuretic Volume Status

ACE Inhibitor or ARB Blood Pressure

Beta Blocker Cardiac Output

Calcium Channel Blocker Cardiac Output

slide-13
SLIDE 13

12/19/15 13

Arrhythmias and Cardiac Amyloidosis

Amiodarone Effective

Anticoagulation Effective

Cardioverter-Defibrillator Possible Benefit

Revascularization Possible Benefit

A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment

  • f Systemic AL Amyloidosis

G Palladini, S Sachchithanantham, et al. Blood 2015;126(5):612-615

slide-14
SLIDE 14

12/19/15 14

AL Cardiac Stage and Survival after CyBorD Therapeutic Clearance of Amyloid by Antibodies to Amyloid P Component

DB Richards, LM Cookson, AC Berges, et al. NEJM 2015;373:1106-1114

slide-15
SLIDE 15

12/19/15 15

99mTechnetium Imaging of Wild-Type TTR Amyloid

Scintigraphy Scan SPECT Imaging

Response to CPHC and Anti-SAP Antibody